These findings suggest that eIF3a exerts pro-fibrotic effects through ERK1/2 pathway activation in bleomycin-induced pulmonary fibrosis, with TGF-β1-mediated eIF3a upregulation being ERK1/2-dependent [15]. The gene discussed is MAPK3; the disease is pulmonary fibrosis.